COLL vs SUPN

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 21. 1x trailing P/E (5. 4x forward), making it the more compelling value choice. Analysts rate Collegium Pharmaceutical, Inc. (COLL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Collegium Pharmaceutical, Inc.

is actually cheaper at 5. 4x.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +75. 7%, compared to +66. 4% for Collegium Pharmaceutical, Inc. (COLL). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus COLL's +153. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Collegium Pharmaceutical, Inc.

(COLL) is the lower-risk stock at 0. 65β versus Supernus Pharmaceuticals, Inc. 's 0. 78β — meaning SUPN is approximately 21% more volatile than COLL relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). On earnings-per-share growth, the picture is similar: Collegium Pharmaceutical, Inc. grew EPS -7. 0% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COLL leads at 24. 0% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 5. 4x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 18. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COLL: 58. 9% to $58. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +153. 1% 10Y return). Both have compounded well over 10 years (COLL: +153. 1%, SUPN: +228. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COLL is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.